The adenosine A sub(2A) receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets

• Published in: European journal of pharmacology 2015-01, Vol.747, p.160-165
• Main Authors: Uchida, Shin-ichi, Soshiroda, Kazuhiro, Okita, Eri, Kawai-Uchida, Mika, Mori, Akihisa, Jenner, Peter, Kanda, Tomoyuki
• Format: Article
• Language: English
• Subjects: Callithrix
• ISSN: 0014-2999
• DOI: 10.1016/j.ejphar.2014.11.038

The adenosine A sub(2A) receptor antagonist, istradefylline, enhances anti-parkinsonian activity in patients with advanced Parkinson's disease (PD) already treated with combinations of L-DOPA and dopamine agonist drugs but who are still exhibiting prolonged 'OFF' periods. In contrast, the effects of istradefylline on motor function when administered in combination with low dose dopamine agonist therapy in early PD are unknown. We now investigate whether istradefylline administered with a threshold dose of either the non-ergot dopamine agonist, ropinirole or the ergot dopamine agonist, pergolide enhances anti-parkinsonian activity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmoset. Both ropinirole (0.01-0.1 mg/kg p.o.) and pergolide (0.003-0.1 mg/kg p.o.) administered alone produced dose dependent increases in locomotor activity, a reduction in motor disability. Threshold doses of ropinirole (0.025-0.075 mg/kg p.o.) and pergolide (0.01-0.075 mg/kg p.o.) were then selected that in individual animals caused a small but non-significant anti-parkinsonian effect. Administration of istradefylline (10 mg/kg p.o.) alone resulted in a decrease in motor disability and increase in 'ON' time but dyskinesia was not observed. Combined administration of pergolide or ropinirole with istradefylline resulted in an increase in the reversal of motor disability and increase in 'ON' time compared to that produced by either treatment alone but dyskinesia was still not observed. These results show that istradefylline is effective in improving motor function when combined with low dose dopamine agonist treatment. In early PD, this may avoid dose escalation or allow a reduction in dopamine agonist dosage without a loss of efficacy and prevent dopaminergic side-effects from becoming treatment limiting. Chemical compounds studied in this article * Istradefylline (PubChem CID: 5311037) * Ropinirole HCl (PubChem CID: 68727) * Pergolide mesylate (PubChem CID: 47812)